Back to top
more

BioTechne Corp (TECH)

(Delayed Data from NSDQ)

$54.64 USD

54.64
2,616,758

-0.24 (-0.44%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $54.63 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

GSK vs. TECH: Which Stock Is the Better Value Option?

by Zacks Equity Research

GSK vs. TECH: Which Stock Is the Better Value Option?

Zacks Equity Research

GSK vs. TECH: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

GSK vs. TECH: Which Stock Is the Better Value Option?

Zacks Equity Research

PBYI or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PBYI vs. TECH: Which Stock Is the Better Value Option?

Zacks Equity Research

PBYI vs. TECH: Which Stock Is the Better Value Option?

by Zacks Equity Research

PBYI vs. TECH: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's What Key Metrics Tell Us About Techne (TECH) Q3 Earnings

by Zacks Equity Research

The headline numbers for Techne (TECH) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Techne (TECH) Meets Q3 Earnings Estimates

by Zacks Equity Research

Techne (TECH) delivered earnings and revenue surprises of 0% and 0.74%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

GSK or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GSK vs. TECH: Which Stock Is the Better Value Option?

Zacks Equity Research

Techne (TECH) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Techne (TECH) delivered earnings and revenue surprises of -4.08% and 6.34%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Illumina (ILMN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Techne (TECH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

REGN or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

REGN vs. TECH: Which Stock Is the Better Value Option?

Zacks Equity Research

Should Vanguard SmallCap Growth ETF (VBK) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for VBK

Zacks Equity Research

GSK or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GSK vs. TECH: Which Stock Is the Better Value Option?

Zacks Equity Research

BIIB vs. TECH: Which Stock Is the Better Value Option?

by Zacks Equity Research

BIIB vs. TECH: Which Stock Is the Better Value Option?

Zacks Equity Research

VRTX or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

VRTX vs. TECH: Which Stock Is the Better Value Option?

Zacks Equity Research

Should Vanguard SmallCap Growth ETF (VBK) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for VBK

Zacks Equity Research

Techne (TECH) Lags Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Techne (TECH) delivered earnings and revenue surprises of -3.78% and 4.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

EXEL or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EXEL vs. TECH: Which Stock Is the Better Value Option?

Zacks Equity Research

EXEL vs. TECH: Which Stock Is the Better Value Option?

by Zacks Equity Research

EXEL vs. TECH: Which Stock Is the Better Value Option?

Zacks Equity Research

Should Vanguard SmallCap Growth ETF (VBK) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for VBK

Zacks Equity Research

Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe

by Zacks Equity Research

Seagen (SGEN) focuses on improving sales of its marketed drugs approved for different types of cancer indications. Stiff competition in the market remains a woe.

Zacks Equity Research

Axsome (AXSM) Q2 Loss Narrower Than Expected, Revenues Miss

by Zacks Equity Research

Axsome (AXSM) reports narrower-than-expected loss for the second quarter of 2022. The company records its first sales of the sleep drug, Sunosi, which it acquired from Jazz.

Zacks Equity Research

Acadia's (ACAD) Q2 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Acadia (ACAD) reports a narrower-than-expected loss for the second quarter of 2022 while revenues surpass estimates. Tightens guidance for Nuplazid.

Zacks Equity Research

Global Blood (GBT) to be Acquired by Pfizer, Misses on Earnings

by Zacks Equity Research

Global Blood (GBT) is set to be acquired by Pfizer for around $5.4 billion. The company missed estimates for earnings while beating the same for revenues in the second quarter of 2022.

Zacks Equity Research

3 Reasons Why Techne (TECH) Is a Great Growth Stock

by Zacks Equity Research

Techne (TECH) possesses solid growth attributes, which could help it handily outperform the market.